The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Balan V.E.

Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii

Andreeva E.N.

Mediko-geneticheskoe otdelenie Moskovskogo oblastnogo NII akusherstva i ginekologii

Il'ina L.M.

Assotsiatsiia ginekologov-éndokrinologov, Moskva

Hormone replscement therapy and breast cancer: scientific evidence and reasons of baseless stable fear (a review)

Authors:

Balan V.E., Andreeva E.N., Il'ina L.M.

More about the authors

Journal: Russian Journal of Human Reproduction. 2013;(4): 103‑111

Read: 8167 times

Download PDF (RU)
Contact the author
Table of contents

HORMONE REPLSCEMENT THERAPY AND BREAST CANCER: SCIENTIFIC EVIDENCE AND REASONS OF BASELESS STABLE FEAR (A REVIEW)
HORMONE REPLSCEMENT THERAPY AND BREAST CANCER: SCIENTIFIC EVIDENCE AND REASONS OF BASELESS STABLE FEAR (A REVIEW)

To cite this article:

Balan VE, Andreeva EN, Il'ina LM. Hormone replscement therapy and breast cancer: scientific evidence and reasons of baseless stable fear (a review). Russian Journal of Human Reproduction. 2013;(4):103‑111. (In Russ.)

Подписка 2026 Проблемы репродукции (Russian Journal of Human Reproduction)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Breast reco­nstruction after single-stage auto­logous reco­nstruction and subsequent flap lipo­necrosis. Plastic Surgery and Aesthetic Medi­cine. 2024;(4):77-83
Free nipple-areolar complex grafting combined with reco­nstruction for unavoidable mastectomy. Plastic Surgery and Aesthetic Medi­cine. 2024;(4):60-64
NDRG1 protein expression in breast cancer samples, rela­tionship with lymph nodes meta­stasis. Russian Journal of Archive of Pathology. 2024;(6):36-42
Impact of tumor size on actuarial survival of patients with primary breast sarcoma: a case-control study. Piro­gov Russian Journal of Surgery. 2024;(12):38-43
Asse­ssment of risk factors for breast cancer deve­lopment in women living in the Sara­tov region. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):100-106
Capsular contracture after reco­nstructive plastic surgery for breast cancer. P.A. Herzen Journal of Onco­logy. 2024;(6):78-83
Left ventricular myocardial performance index (Tei index) as an early marker of cardiotoxicity in anti­tumor therapy. Russian Cardiology Bulletin. 2024;(4-2):137-143
Nottingham Prognostic Index rela­tion to cyto­kine-producing tumor mole­cular subtypes in breast cancer. Russian Journal of Preventive Medi­cine. 2025;(1):63-68
The possibilities of predicting and redu­cing the risk of breast cancer in women against the background of the use of assi­sted reproductive technologies. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):59-64
Neoadjuvant drug therapy and onco­logical outcomes in patients with stage I–II breast cancer. P.A. Herzen Journal of Onco­logy. 2025;(1):5-12
Abstract:

Authors:

Balan V.E.

Moskovskiĭ oblastnoĭ NII akusherstva i ginekologii

Andreeva E.N.

Mediko-geneticheskoe otdelenie Moskovskogo oblastnogo NII akusherstva i ginekologii

Il'ina L.M.

Assotsiatsiia ginekologov-éndokrinologov, Moskva

Close metadata

References:

  1. Ul'rikh E.A., Urmancheeva A.F. Onkologicheskie aspekty zamestitel'noi menopauzal'noi gormonal'noi terapii. Prakt onkol 2009; 10: 2: 76-83.
  2. US Cancer Statistics Working Group. United States Cancer Statistics: 1999-2009 Incidence and Mortality Web-based Report. Atlanta (GA) 2013.
  3. Smetnik V.P., Konovalova V.N. Zamestitel'naya gormonoterapiya i risk raka molochnykh zhelez u zhenshchin v postmenopuze: analiz nekotorykh epidemiologicheskikh issledovanii. Ros onkol zhurn 2011; 2: 53-56.
  4. Gompel A., Santen R.J. Hormone therapy and breast cancer risk 10 years after the WHI. Climacteric 2012; 15: 241-249.
  5. Shapiro S., Farmer R.D., Stevenson J.C. et al. Does hormone replacement therapy (HRT) cause breast cancer? An application of causal principles to three studies: Part 5. Trends in breast cancer incidence in relation to the use of HRT. J Fam Plann Reprod Health Care 2013; 39: 39: 80-88.
  6. Trichopoulos D., Adami H.-O., Ekbom A. et al. Early life events and conditions and breast cancer risk: from epidemiology to etiology. In J Cancer 2008; 122: 481-485.
  7. Bush T.L., Whiteman M., Flaws J.A. et al. Hormone replacement therapy and breast cancer: a qualitative review. Obstet Gynecol 2001; 98: 498-508.
  8. Rossouw J.E., Anderson G.L., Prentice R.L. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288: 321-333.
  9. Chlebowski R.T., Hendrix S.L., Langer R.D. et al. for the WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003; 289: 3243-3253.
  10. Beral V., Banks E., Reeves G., Bull D. for the MillionWomen Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-427.
  11. Ettinger B., Wang S.M., Leslie R.S. et al. Evolution of postmenopausal hormone therapy between 2002 and 2009. Menopause 2012; 19: 6: 610-615.
  12. Steinkellner A.R., Denison S.E., Eldridge S.L. et al. A decade of postmenopausal hormone therapy prescribing in the United States: long-term effects of the Women's Health Initiative. Menopause 2012; 19: 6: 616-621.
  13. Cumming G.P., Currie H.D., Panay N., Moncur R., Lee A.J. Stopping hormone replacement therapy: were women ill advised? Menopause Int 2011; 17: 82-87.
  14. Ockene J.K., Barad D.H., Cochrane B.B. et al. Symptom experience after discontinuing use of estrogen plus progestin. JAMA 2005; 294: 183-193.
  15. Karim R., Dell R.M., Greene D.F. et al. Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization. Menopause 2011; 18: 11: 1172-1177.
  16. Steinkellner A.R., Denison S.E., Eldridge S.L. et al. A decade of postmenopausal hormone therapy prescribing in the United States: long-term effects of the Women's Health Initiative. Menopause 2012; 19: 6: 616-621.
  17. Colditz G.A., Stampfer M.J., Willett W.C. et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589-1589.
  18. Collaborative Group on Hormonal factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997; 350: 1047-1059.
  19. Chen Y.C., Colditz G.A., Rosner B. et al. Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Int Med 2006; 166: 1027-1032.
  20. Shapiro S., Farmer R.D., Stevenson J.C. et al. Does hormone replacement therapy cause breast cancer? An application of causal principles to three studies Part 4: The Million Women Study. J Fam Plann Reprod Health Care 2012; 38: 102-109.
  21. Hulley S., Furberg C., Barrett-Connor E. et al. Noncardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II) for the HERS Research Group. JAMA 2002; 288: 58-64.
  22. Marjoribanks J., Farquhar C., Roberts H., Lethaby A. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2012; 7: CD004143.
  23. Anderson G.L., Limacher M., Assaf A.R. et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701-1712.
  24. Stefanick M.L., Anderson G.L., Margolis K.L. et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006; 295: 1647-1657.
  25. Anderson R.G., Chlebowski R.T., Aragaki A.K. et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol 2012; 13: 5: 476-486.
  26. Bluming A.Z., Tavris C. Chains of evidence, mosaics of data: does estrogen "cause" breast cancer? How would we know? Chains of evidence, mosaics of data: does estrogen "cause" breast cancer? How would we know? Climacteric 2012; 15: 531-537.
  27. Craig-Jordan V., Lewis-Wambi J., Kim H. et al. Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients. Breast 2007; 16: Suppl: 2: 105-113.
  28. Obiorah I., Jordan V.C. Scientific rationale for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality. Menopause 2013; 20: 4: 372-382.
  29. Preston-Martin S., Pike M.C., Ross R.K., Henderson B.E. Epidemiologic evidence for the increased cell proliferation model of carcinogenesis. Environ Health Perspect 1993; 101: Suppl: 5: 137-138.
  30. Yager J.D., Davidson N.E. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006; 354: 270-282.
  31. Shapiro S., Farmer R.D.T., Mueck A.O., Seaman H., Stevenson J.C. Does hormone therapy cause breast cancer? An application of causal principles to three studies. Part 3. The Women's Health Initiative: estrogen plus progestogen. J Fam Plann Reprod Health Care 2011; 37: 165-172.
  32. de Villiers T.J., Pines A., Panay N. et al. on behalf of the International Menopause Society. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 2013; 16: 316-337.
  33. Kenemans P., Speroff L. International Tibolone Consensus Group. Tibolone: Clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas 2005; 51: 21-28.
  34. Cummings S.R. et al. The effects of Tibolone in older postmenopausal women. N Engl J Med 2008; 359: 697-708.
  35. Chen Z., Arendell L., Aickin M. et al. Hip bone density predicts breast cancer risk independently of Gail score: results from the Women's Health Initiative. Cancer 2008; 113: 907-915.
  36. Gompel A., Rozenberg S., Barlow D.H. The EMAS board member. The EMAS 2008 update on clinical recommendations on postmenopausal hormone replacement therapy. Maturitas 2008; 61: 227-232.
  37. Kenemans P. et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, noninferiority trial. Lancet Oncol 2009; 10: 2: 135-146.
  38. The North American Menopause Society. The 2012 Hormone Therapy Position Statement of The North American Menopause Society. Menopause 2012; 19: 257.
  39. Anderson G.L., Chlebowski R.T., Aragaki A.K. et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol 2011; 13: 476-86.
  40. Chlebowski R.T., Anderson G. C hanging concepts: menopausal hormone therapy and breast cancer. J Natl Cancer Inst 2012; 104: 517-527.
  41. Schierbeck L.L., Rejnmark L., Tofteng C.L. et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: Randomised trial. BMJ 2012; DOI: 10.1136/bmj.e6409.
  42. Kronos Longevity Research Institute. Hormone therapy has many favorable effects in newly menopausal women: Initial findings of the Kronos Early Estrogen Prevention Study (KEEPS). Press release dated 3 October 2012. http://www.menopause.org docs/agm/general-release.
  43. de Lignieresa B., de Vathairea F., Fourniera S. et al. Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3 175 women. Climacteric 2002; 5: 332: 332-340.
  44. Fournier A., Berrino F., Clavel-Chapelon F. et al. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Br Cancer Res Treat 2008; 107: 307-308.
  45. Lyytinen H., Pukkala E., Ylikorkala O. Breast cancer risk in postmenopausalwomenusingestradiol-progestogentherapy. Obstet Gynecol 2009; 113: 65-73.
  46. Bakken K., Fournier A.S., Lund E. et al. Menopausal hormone therapy and breast cancer risk: impact of different treatments. The European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2011; 128: 144-156.
  47. Santen R.J., Allred D.C., Ardoin C.A. et al. Postmenopausal Hormone Therapy. An Endocrine Society Scientific Statement. J Clin Endocrinol Metabol 2010; 95: Suppl: 1: 1-66.
  48. Santen R.J. Risk of breast cancer with progestins: critical assessment of current data. Steroids 2003; 68: 953-964.
  49. Ross R.K. et al. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000; 92: 328-332.
  50. Horwitz K.B. et al. Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl Acad Sci USA 2008; 105: 5774-5779.
  51. Wiebe J.P. et al. The 4-pregnene and 5α-pregnane progesterone metabolites formed in nontumorous and tumorous breast tissue have opposite effects on breast cell proliferation and adhesion. Cancer Res 2000; 60: 936-943.
  52. Bray J.D., Jelinsky S., Ghatge R. et al. Quantitative analysis of gene regulation by seven clinically relevant progestins suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells. J Steroid Biochem Mol Biol 2005; 97: 328-341.
  53. Fu X.D., Giretti M.S., Goglia L. et al. Comparative actions of progesterone, medroxyprogesterone acetate, drospirenone and nestorone on breast cancer cell migration and invasion. BMC Cancer 2008; 8: 166.
  54. Otto C., Fuchs I., Altmann H. et al. Comparative analysis of the uterine and mammary gland effects of drospirenone and medroxyprogesterone acetate. Endocrinology 2008; 149: 8: 3952-3959.
  55. Hofseth L.J., Raafat A.M., Osuch J.R. et al. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metabol 1999; 84: 4559-4565.
  56. Heinemann K., Assmann A., Dinger J. The Safety of Oral Hormone Replacement Therapy: Final Results from the EURAS-HRT Study. Pharmacoepidemiol Drug Safety 2012; 21: Suppl: 3: 365.
  57. Pichad C., Plu-Bureau G., Nevese Castro M., Gompel A. Insulin resistance, obesity and breast cancer risk. Maturitas 2008; 60: 10-18.
  58. Dietel M., Lewis M.A., Shapiro S. et al. Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Human Reprod 2005; 20: 2052-2060.
  59. de Villiers T.J., Gass M.L.S., Haines C.J. et al. Global Consensus Statement on Menopausal Hormone Therapy. Climacteric 2013; 16: 203-204.
  60. Panay N., Fenton A. (editorial). A global consensus statement on menopause hormone therapy - aims, aspirations and action points. Climacteric 2013; 16: 201-202.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.